|
시장보고서
상품코드
1786799
NAMPT 억제제 시장 : 시장 규모, 점유율, 동향, 산업 분석(분자 유형별, 단계별, 투여 경로별, 용도별, 지역별) 및 예측(2025-2034년)NAMPT Inhibitors Market Size, Share, Trends, & Industry Analysis Report By Type of Molecule (Small Molecules and Biologics), By Phase, By Route of Administration, By Application, and By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면, NAMPT 억제제 시장 규모는 2034년까지 55억 2,000만 달러에 달할 것으로 예측됩니다. 이 조사 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.
NAMPT 억제제 시장은 제약사들이 세포의 에너지 대사를 표적으로 하는 새로운 치료제 개발에 집중하면서 성장하고 있습니다. NAMPT는 니코틴아미디아데닌디뉴클레오티드(NAD+) 생합성 경로의 중요한 효소이며, 암세포의 성장과 생존을 지원합니다. 이 효소를 억제하면 종양세포의 에너지 공급이 제한되어 치료에 더 취약해집니다.
현재 진행 중인 임상 연구와 전임상시험의 진전은 암 분야 파이프라인에서 NAMPT 억제제의 채택을 촉진하고 있습니다. 이들 억제제는 치료 효과를 개선하기 위해 단독요법과 병용요법 모두 검토되고 있습니다. 바이오기업과 제약사들의 관심이 높아진 데다, 표적항암제에 대한 규제 당국의 지원 체계가 잘 갖춰져 있어 시장 성장을 가속화하고 있습니다.
NAMPT 억제제 시장 보고서 하이라이트
분자 유형별로는 저분자 화합물이 우수한 약동학을 보이고, 제형화가 용이하며, 암 치료제 시장 개척에 있어 확고한 역할을 수행하기 때문에 2024년 시장 점유율은 저분자 화합물이 우위를 차지했습니다.
단계별로는 전임상 부문이 2024년 시장을 독점했습니다. 이는 대부분의 NAMPT 억제제 프로그램이 초기 단계에 있기 때문이며, 후보 화합물은 in vitro 및 in vivo에서 광범위한 시험을 실시하여 효능, 독성, 약력학적 특성을 평가하기 때문입니다.
투여 경로별로는 제어된 약물전달, 안정적인 생체 이용률, 빠른 전신 노출이 가능한 정맥 투여가 2024년 시장을 주도했습니다.
용도별로는 백혈병, 림프종 등 혈액암 치료의 역할 확대와 이 분야의 임상 연구 활동 활성화에 힘입어 혈액학 분야가 2034년까지 가장 높은 성장률을 보일 것으로 예측됩니다.
2024년 NAMPT 억제제 세계 시장은 암 연구 및 초기 단계의 신약개발에 대한 막대한 투자로 인해 북미가 대부분을 차지했습니다.
아시아태평양은 가장 빠르게 성장하는 시장으로, 이 지역의 생명공학 상황의 확대와 국제 공동 연구 참여 확대가 그 요인으로 작용하고 있습니다.
세계 주요 기업으로는 AbbVie Inc., Angelini Pharma S.p.A., Antengene Therapeutics Limited, Aqualung Therapeutics Corporation, AstraZeneca plc, Bayer AG, Boehringer Ingelheim GmbH, Calico LLC, FORMA Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline plc (GSK plc), Johnson & Johnson Services, Inc., Karyopharm Therapeutics Inc., Merck & Co., Inc., Novartis AG. 등이 있습니다.
목차
제1장 소개
제2장 주요 요약
제3장 조사 방법
제4장 세계의 NAMPT 억제제 시장 인사이트
- 시장 현황
- NAMPT 억제제 시장 역학
- 성장 촉진요인과 기회
- 지원적인 규제와 자금 조달 환경
- 세계의 암 부담 증대
- 성장 억제요인과 과제
- 독성과 안전성에 관한 우려
- 성장 촉진요인과 기회
- PESTEL 분석
- NAMPT 억제제 시장 동향
- 밸류체인 분석
제5장 세계의 NAMPT 억제제 시장 : 분자 유형별
- 주요 조사 결과
- 소개
- 소분자
- 생물학적 제제
제6장 세계의 NAMPT 억제제 시장 : 단계별
- 주요 조사 결과
- 소개
- 단계 I
- 단계 II
- 단계 I/II
- 전임상
제7장 세계의 NAMPT 억제제 시장 : 투여 경로별
- 주요 조사 결과
- 소개
- 경구
- 정맥내
제8장 세계의 NAMPT 억제제 시장 : 용도별
- 주요 조사 결과
- 소개
- 종양학
- 혈액학
- 염증성 및 대사성 질환
- 신경학
- 기타
제9장 세계의 NAMPT 억제제 시장 : 지역별
- 주요 조사 결과
- 소개
- NAMPT 억제제 시장 분석 : 지역별, 2020-2034년
- 북미
- 북미 : 분자 유형별, 2020-2034년
- 북미 : 단계별, 2020-2034년
- 북미 : 투여 경로별, 2020-2034년
- 북미 : 용도별, 2020-2034년
- 미국
- 캐나다
- 유럽
- 유럽 : 분자 유형별, 2020-2034년
- 유럽 : 단계별, 2020-2034년
- 유럽 : 투여 경로별, 2020-2034년
- 유럽 : 용도별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 분자 유형별, 2020-2034년
- 아시아태평양 : 단계별, 2020-2034년
- 아시아태평양 : 투여 경로별, 2020-2034년
- 아시아태평양 : 용도별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 분자 유형별, 2020-2034년
- 중동 및 아프리카 : 단계별, 2020-2034년
- 중동 및 아프리카 : 투여 경로별, 2020-2034년
- 중동 및 아프리카 : 용도별, 2020-2034년
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 분자 유형별, 2020-2034년
- 라틴아메리카 : 단계별, 2020-2034년
- 라틴아메리카 : 투여 경로별, 2020-2034년
- 라틴아메리카 : 용도별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제10장 경쟁 구도
- 확대와 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제11장 기업 개요
- AbbVie Inc.
- Angelini Pharma S.p.A.
- Antengene Therapeutics Limited
- Aqualung Therapeutics Corporation
- AstraZeneca plc
- Bayer AG
- Boehringer Ingelheim GmbH
- Calico LLC
- FORMA Therapeutics, Inc.
- Genentech, Inc.
- GlaxoSmithKline plc(GSK plc)
- Johnson & Johnson Services, Inc.
The NAMPT inhibitors market size is expected to reach USD 5.52 Billion by 2034, according to a new study by Polaris Market Research. The report "NAMPT Inhibitors Market Size, Share, Trends, & Industry Analysis Report By Type of Molecule (Small Molecules and Biologics), By Phase, By Route of Administration, By Application, and By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The NAMPT inhibitors market is growing as pharmaceutical companies focus on developing new therapies targeting cellular energy metabolism. NAMPT is a key enzyme in the Nicotinamide Adenine Dinucleotide (NAD+) biosynthesis pathway, which supports cancer cell growth and survival. Inhibiting this enzyme helps limit energy supply to tumor cells, making them more vulnerable to treatment.
Ongoing clinical research and preclinical advancements are driving the adoption of NAMPT inhibitors across oncology pipelines. These inhibitors are explored as both standalone and combination therapies to improve treatment response. The growing interest from biotech and pharmaceutical firms, along with supportive regulatory pathways for targeted oncology drugs, is accelerating the market growth.
NAMPT Inhibitors Market Report Highlights
Based on type of molecule, the small molecules segment dominated the market share in 2024, due to its favorable pharmacokinetics, ease of formulation, and established role in oncology drug development.
In terms of phase, the preclinical segment dominated the market in 2024. This is owing to the early stage of most NAMPT inhibitor programs, as candidates undergo extensive in vitro and in vivo testing to evaluate efficacy, toxicity, and pharmacodynamic properties.
In terms of route of administration, the intravenous (IV) administration segment dominated the market in 2024, attributed to its ability to ensure controlled drug delivery, consistent bioavailability, and rapid systemic exposure.
Based on application, the hematology segment is projected to grow at the highest rate by 2034, driven by its expanding role in the treatment of blood cancers such as leukemia and lymphoma, supported by growing clinical research activity in this area.
North America accounted for the majority share in the global NAMPT inhibitors market in 2024, due to substantial investments in oncology research and early-phase drug discovery.
Asia Pacific is the fastest growing market, driven by the expanding regional biotech landscape and greater involvement in international research collaborations.
A few global key market players include AbbVie Inc., Angelini Pharma S.p.A., Antengene Therapeutics Limited, Aqualung Therapeutics Corporation, AstraZeneca plc, Bayer AG, Boehringer Ingelheim GmbH, Calico LLC, FORMA Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline plc (GSK plc), Johnson & Johnson Services, Inc., Karyopharm Therapeutics Inc., Merck & Co., Inc., and Novartis AG.
Polaris Market Research has segmented the market report on the basis of type of molecule, phase, route of administration, application, and region:
By Type of Molecule Outlook (Revenue, USD Billion, 2020-2034)
Small Molecules
Biologics
By Phase Outlook (Revenue, USD Billion, 2020-2034)
Phase I
Phase II
Phase I/II
Preclinical
By Route of Administration Outlook (Revenue, USD Billion, 2020-2034)
Oral
Intravenous
By Application Outlook (Revenue, USD Billion, 2020-2034)
Oncology
Hematology
Inflammatory and Metabolic Diseases
Neurology
Others
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global NAMPT Inhibitors Market Insights
- 4.1. NAMPT Inhibitors Market - Market Snapshot
- 4.2. NAMPT Inhibitors Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Supportive Regulatory and Funding Environment
- 4.2.1.2. Increasing Global Cancer Burden
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Toxicity and Safety Concerns
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. NAMPT Inhibitors Market Trends
- 4.6. Value Chain Analysis
5. Global NAMPT Inhibitors Market, by Type of Molecule
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 5.3. Small Molecules
- 5.3.1. Global NAMPT Inhibitors Market, by Small Molecules, by Region, 2020-2034 (USD Billion)
- 5.4. Biologics
- 5.4.1. Global NAMPT Inhibitors Market, by Biologics, by Region, 2020-2034 (USD Billion)
6. Global NAMPT Inhibitors Market, by Phase
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 6.3. Phase I
- 6.3.1. Global NAMPT Inhibitors Market, by Phase I, by Region, 2020-2034 (USD Billion)
- 6.4. Phase II
- 6.4.1. Global NAMPT Inhibitors Market, by Phase II, by Region, 2020-2034 (USD Billion)
- 6.5. Phase I/II
- 6.5.1. Global NAMPT Inhibitors Market, by Phase I/II, by Region, 2020-2034 (USD Billion)
- 6.6. Preclinical
- 6.6.1. Global NAMPT Inhibitors Market, by Preclinical, by Region, 2020-2034 (USD Billion)
7. Global NAMPT Inhibitors Market, by Route of Administration
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 7.3. Oral
- 7.3.1. Global NAMPT Inhibitors Market, by Oral, by Region, 2020-2034 (USD Billion)
- 7.4. Intravenous
- 7.4.1. Global NAMPT Inhibitors Market, by Intravenous, by Region, 2020-2034 (USD Billion)
8. Global NAMPT Inhibitors Market, by Application
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 8.3. Oncology
- 8.3.1. Global NAMPT Inhibitors Market, by Oncology, by Region, 2020-2034 (USD Billion)
- 8.4. Hematology
- 8.4.1. Global NAMPT Inhibitors Market, by Hematology, by Region, 2020-2034 (USD Billion)
- 8.5. Inflammatory and Metabolic Diseases
- 8.5.1. Global NAMPT Inhibitors Market, by Inflammatory and Metabolic Diseases, by Region, 2020-2034 (USD Billion)
- 8.6. Neurology
- 8.6.1. Global NAMPT Inhibitors Market, by Neurology, by Region, 2020-2034 (USD Billion)
- 8.7. Others
- 8.7.1. NAMPT Inhibitors Market, by Others, by Region, 2020-2034 (USD Billion)
9. Global NAMPT Inhibitors Market, by Geography
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. NAMPT Inhibitors Market Assessment, By Geography, 2020-2034 (USD Billion)
- 9.3. NAMPT Inhibitors Market - North America
- 9.3.1. North America: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.3.2. North America: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.3.3. North America: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.3.4. North America: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.3.5. NAMPT Inhibitors Market - U.S.
- 9.3.5.1. U.S.: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.3.5.2. U.S.: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.3.5.3. U.S.: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.3.5.4. U.S.: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.3.6. NAMPT Inhibitors Market - Canada
- 9.3.6.1. Canada: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.3.6.2. Canada: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.3.6.3. Canada: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.3.6.4. Canada: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.4. NAMPT Inhibitors Market - Europe
- 9.4.1. Europe: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.4.2. Europe: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.4.3. Europe: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.4. Europe: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.4.5. NAMPT Inhibitors Market - UK
- 9.4.5.1. UK: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.4.5.2. UK: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.4.5.3. UK: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.5.4. UK: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.4.6. NAMPT Inhibitors Market - France
- 9.4.6.1. France: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.4.6.2. France: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.4.6.3. France: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.6.4. France: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.4.7. NAMPT Inhibitors Market - Germany
- 9.4.7.1. Germany: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.4.7.2. Germany: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.4.7.3. Germany: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.7.4. Germany: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.4.8. NAMPT Inhibitors Market - Italy
- 9.4.8.1. Italy: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.4.8.2. Italy: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.4.8.3. Italy: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.8.4. Italy: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.4.9. NAMPT Inhibitors Market - Spain
- 9.4.9.1. Spain: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.4.9.2. Spain: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.4.9.3. Spain: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.9.4. Spain: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.4.10. NAMPT Inhibitors Market - Netherlands
- 9.4.10.1. Netherlands: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.4.10.2. Netherlands: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.4.10.3. Netherlands: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.10.4. Netherlands: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.4.11. NAMPT Inhibitors Market - Russia
- 9.4.11.1. Russia: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.4.11.2. Russia: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.4.11.3. Russia: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.11.4. Russia: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.4.12. NAMPT Inhibitors Market - Rest of Europe
- 9.4.12.1. Rest of Europe: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.4.12.2. Rest of Europe: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.4.12.3. Rest of Europe: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.12.4. Rest of Europe: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.5. NAMPT Inhibitors Market - Asia Pacific
- 9.5.1. Asia Pacific: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.5.2. Asia Pacific: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.5.3. Asia Pacific: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.4. Asia Pacific: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.5.5. NAMPT Inhibitors Market - China
- 9.5.5.1. China: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.5.5.2. China: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.5.5.3. China: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.5.4. China: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.5.6. NAMPT Inhibitors Market - India
- 9.5.6.1. India: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.5.6.2. India: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.5.6.3. India: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.6.4. India: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.5.7. NAMPT Inhibitors Market - Malaysia
- 9.5.7.1. Malaysia: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.5.7.2. Malaysia: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.5.7.3. Malaysia: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.7.4. Malaysia: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.5.8. NAMPT Inhibitors Market - Japan
- 9.5.8.1. Japan: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.5.8.2. Japan: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.5.8.3. Japan: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.8.4. Japan: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.5.9. NAMPT Inhibitors Market - Indonesia
- 9.5.9.1. Indonesia: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.5.9.2. Indonesia: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.5.9.3. Indonesia: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.9.4. Indonesia: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.5.10. NAMPT Inhibitors Market - South Korea
- 9.5.10.1. South Korea: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.5.10.2. South Korea: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.5.10.3. South Korea: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.10.4. South Korea: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.5.11. NAMPT Inhibitors Market - Australia
- 9.5.11.1. Australia: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.5.11.2. Australia: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.5.11.3. Australia: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.11.4. Australia: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.5.12. NAMPT Inhibitors Market - Rest of Asia Pacific
- 9.5.12.1. Rest of Asia Pacific: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.5.12.2. Rest of Asia Pacific: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.5.12.3. Rest of Asia Pacific: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.12.4. Rest of Asia Pacific: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.6. NAMPT Inhibitors Market - Middle East & Africa
- 9.6.1. Middle East & Africa: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.6.2. Middle East & Africa: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.6.3. Middle East & Africa: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.4. Middle East & Africa: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.6.5. NAMPT Inhibitors Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.6.5.2. Saudi Arabia: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.6.5.3. Saudi Arabia: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.5.4. Saudi Arabia: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.6.6. NAMPT Inhibitors Market - UAE
- 9.6.6.1. UAE: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.6.6.2. UAE: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.6.6.3. UAE: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.6.4. UAE: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.6.7. NAMPT Inhibitors Market - Israel
- 9.6.7.1. Israel: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.6.7.2. Israel: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.6.7.3. Israel: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.7.4. Israel: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.6.8. NAMPT Inhibitors Market - South Africa
- 9.6.8.1. South Africa: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.6.8.2. South Africa: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.6.8.3. South Africa: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.8.4. South Africa: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.6.9. NAMPT Inhibitors Market - Rest of Middle East & Africa
- 9.6.9.1. Rest of Middle East & Africa: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.6.9.2. Rest of Middle East & Africa: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.6.9.3. Rest of Middle East & Africa: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.9.4. Rest of Middle East & Africa: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.7. NAMPT Inhibitors Market - Latin America
- 9.7.1. Latin America: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.7.2. Latin America: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.7.3. Latin America: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.7.4. Latin America: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.7.5. NAMPT Inhibitors Market - Mexico
- 9.7.5.1. Mexico: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.7.5.2. Mexico: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.7.5.3. Mexico: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.7.5.4. Mexico: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.7.6. NAMPT Inhibitors Market - Brazil
- 9.7.6.1. Brazil: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.7.6.2. Brazil: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.7.6.3. Brazil: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.7.6.4. Brazil: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.7.7. NAMPT Inhibitors Market - Argentina
- 9.7.7.1. Argentina: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.7.7.2. Argentina: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.7.7.3. Argentina: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.7.7.4. Argentina: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
- 9.7.8. NAMPT Inhibitors Market - Rest of Latin America
- 9.7.8.1. Rest of Latin America: NAMPT Inhibitors Market, by Type of Molecule, 2020-2034 (USD Billion)
- 9.7.8.2. Rest of Latin America: NAMPT Inhibitors Market, by Phase, 2020-2034 (USD Billion)
- 9.7.8.3. Rest of Latin America: NAMPT Inhibitors Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.7.8.4. Rest of Latin America: NAMPT Inhibitors Market, by Application, 2020-2034 (USD Billion)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. AbbVie Inc.
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Angelini Pharma S.p.A.
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. Antengene Therapeutics Limited
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. Aqualung Therapeutics Corporation
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. AstraZeneca plc
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. Bayer AG
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. Boehringer Ingelheim GmbH
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. Calico LLC
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. FORMA Therapeutics, Inc.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. Genentech, Inc.
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
- 11.11. GlaxoSmithKline plc (GSK plc)
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
- 11.12. Johnson & Johnson Services, Inc.
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Benchmarking
- 11.12.4. Recent Development
(주말 및 공휴일 제외)
